<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505307</url>
  </required_header>
  <id_info>
    <org_study_id>D0816C00019</org_study_id>
    <nct_id>NCT03505307</nct_id>
  </id_info>
  <brief_title>Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)</brief_title>
  <official_title>Lynparza Tablets 100mg, 150mg Clinical Experience Investigation (All Case Investigation) in Patients With Platinum-sensitive Relapsed Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      [Objectives] Objectives include following to capture safety and efficacy of LYNPARZA in&#xD;
      actual clinical use.&#xD;
&#xD;
        1. ADR development in actual clinical use&#xD;
&#xD;
        2. Factors which may affect safety and efficacy&#xD;
&#xD;
        3. ADRs not expected from &quot;Precautions for Use&quot;&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the Clinical Experience Investigation (CEI) is to collect following data to&#xD;
      characterise safety and efficacy of LYMPARZA Tablets 100mg and 150mg (LYMPARZA) in usual&#xD;
      post-marketing use.&#xD;
&#xD;
        1. Development of adverse drug reactions (ADRs)&#xD;
&#xD;
        2. Factors which may affect safety and efficacy of LYMPARZA&#xD;
&#xD;
        3. Development of adverse drug reactions (ADRs) unexpected from &quot;Precautions for Use&quot; of&#xD;
           the LYMPARZA JPI&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2018</start_date>
  <completion_date type="Actual">December 7, 2020</completion_date>
  <primary_completion_date type="Actual">December 7, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of ADRs regarding Bone marrow depression, ILD, new primary malignancies, Embryo-foetal toxicity and exposure in patient with renal impairment</measure>
    <time_frame>from baseline to 1 year</time_frame>
    <description>To be calculated incidence of ADRs related to LYMPARZA during the observation period regarding Bone marrow depression, ILD, new primary malignancies, Embryo-foetal toxicity and exposure in patient with renal impairment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors which may impact incidence of ADRs related to LYMPARZA during the observation period, analysed by patient demographic characteristics</measure>
    <time_frame>from baseline to 1 year</time_frame>
    <description>Factors which may impact incidence of ADRs, analysed by patient demographic characteristic(past medical history, and concomitant disease etc)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of ADRs not expected from &quot;Precautions for Use&quot; of LYNPARZA JPI</measure>
    <time_frame>from baseline to 1 year</time_frame>
    <description>To be calculated incidence of ADRs related to LYMPARZA during the observation period not expected from &quot;Precautions for Use&quot; of LYNPARZA JPI</description>
  </primary_outcome>
  <enrollment type="Actual">846</enrollment>
  <condition>Ovarian Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with LYNPARZA for ovarian cancer which is the indication of the drug&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Maintenance treatment for patients with recurrent ovarian cancer, who are sensitive to&#xD;
             platinum based chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshimitsu Tokimoto</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca KK</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 10, 2018</study_first_submitted>
  <study_first_submitted_qc>April 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.&#xD;
All request will be evaluated as per the AZ disclosure commitment:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

